Infectious disease
Researchers at the virtual 7th Congress of the European Academy of Neurology consistently report significant, lingering cognitive and behavioral problems in multiple studies.
Though the world is reopening, this pandemic is not over. Moderna continues expanding production to answer the call globally.
Findings from the study suggest the oral JAK inhibitor tofacitinib could be a potential contender in the race to identify benefits for COVID-19 in already approved therapies.
Scientists call for more investigation into the origin of the virus, particularly in China, but China now wants to include the U.S. in the probe.
The new findings likely throw a wrench in the company’s plans to deliver millions of much-needed vaccine doses to the European Union soon.
The company’s lead candidate, INNA-051, is an innate immune agonist that directly stimulates the host’s natural immune defense system.
The new data shows REGEN-COV reduced the risk of death in hospitalized patients unable to mount their own immune response by 20%.
Repurposed drugs became the front-line defense against COVID-19 within a few months of the pandemic’s emergence. Now bucillamine, currently in Phase III trials in the U.S., may be poised to join them.
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 15, 2021.
PRESS RELEASES